GlobalData on MSN
Abbott reports positive FREEDM2 study results for CGM
The study was carried out at 24 clinical sites across the UK and included 303 participants.
Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results